Overview

Safety and Efficacy of IBI389 Single Agent and in Combination With Sintilimab in Patients With Advanced Malignancies

Status:
Not yet recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
This study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of IBI389 as a single agent and in combination with sintilimab and (or) chemotherapy in patients with advanced or metastatic solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.